Oppenheimer Reiterates Outperform on Capricor Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell has reiterated an 'Outperform' rating for Capricor Therapeutics, maintaining a price target of $15.
September 23, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer has reiterated its 'Outperform' rating for Capricor Therapeutics, maintaining a $15 price target, indicating confidence in the company's future performance.
The reiteration of an 'Outperform' rating and maintenance of a $15 price target by Oppenheimer suggests positive sentiment and confidence in Capricor Therapeutics' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100